BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 4th Quarter - Report

AVADEL PHARMACEUTICALS

via THE MCMANUS GROUP

4th Quarter (Oct 1 - Dec 31) · 2022Posted Jan 20, 2023Filing document ↗LDA record ↗

Income$50Kfee reported

Client

Name: AVADEL PHARMACEUTICALS
Description: Biopharmaceuticals
Location: Missouri · United States of America

Registrant

Firm: THE MCMANUS GROUP
Description: Consulting
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medicare/Medicaid
Increased access to narcoleptic medication (S.4918 - Increasing Prescription Drug Competition Act)
LobbyistsJOHN MCMANUS · ALANNA TEMME
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

AVADEL PHARMACEUTICALS — Lobbying — Receipts Report